MRTX - Mirati Therapeutics, Inc.
| Previous Close | 72.62 |
| Open | 72.62 |
| Bid | 71.00 x 800 |
| Ask | 76.00 x 1100 |
| Day's Range | 72.62 - 72.62 |
| 52 Week Range | 24.65 - 76.00 |
| Volume | 4,158 |
| Avg. Volume | 617,380 |
| Market Cap | 2.478B |
| Beta (3Y Monthly) | 2.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.99 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.36 |
- PR Newswire•12 days ago
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology ...
- Motley Fool•15 days ago
Here's Why Mirati Therapeutics Jumped 55.8% in January
Investors cheered the biotech's plans to move its lead candidate forward.
- ACCESSWIRE•19 days ago
Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
- Simply Wall St.•20 days ago
How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- Benzinga•27 days ago
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
- PR Newswire•28 days ago
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO , Jan. 22, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common ...
- Benzinga•last month
The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
- PR Newswire•last month
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has also granted the underwriters a 30-day option to purchase up to an additional 241,935 shares of common stock in connection with the public offering.
- PR Newswire•last month
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares are being offered by Mirati.
- PR Newswire•last month
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations. "Today we have achieved an important milestone in the battle against cancers driven by KRAS mutations, one of the most common and difficult to treat patient populations. MRTX849 has been designed to specifically target KRAS G12C mutations, which are thought to be responsible for at least 14% of non-small cell lung adenocarcinoma, 4% of colorectal cancer, and subsets of other types of cancers," said Charles Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
- ACCESSWIRE•last month
Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.
- Zacks•last month
Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- PR Newswire•last month
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
SAN DIEGO , Jan. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company ...
- PR Newswire•2 months ago
Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 2, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco ...
- PR Newswire•2 months ago
Mirati Therapeutics Added To NASDAQ Biotechnology Index
SAN DIEGO , Dec. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology ...
- Insider Monkey•2 months ago
Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- PR Newswire•2 months ago
Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
SAN DIEGO , Dec. 10, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board ...
- GlobeNewswire•3 months ago
Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Benzinga•3 months ago
The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 29) Allakos Inc (NASDAQ: ALLK ) Emergent Biosolutions Inc ...
- PR Newswire•3 months ago
Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
"KRAS mutations, like the G12C mutation, are recognized as drivers of multiple tumor types, including non-small cell lung cancer and colorectal cancers. Efforts over the last 25 years to develop drugs to inhibit mutant KRAS have been largely unsuccessful," said James Christensen, Ph.D., Chief Scientific Officer, Mirati Therapeutics.
Market Realist•3 months agoMirati Therapeutics Stock Has Delivered Solid Growth in 2018
Mirati Therapeutics hit a 52-week high of $65.35 on July 31. In November, Mirati Therapeutics presented the preliminary biomarker data from the ongoing Phase 2 clinical trial of its sitravatinib and Bristol-Myers Squibb’s Opdivo combination therapy. Mirati Therapeutics is conducting the Phase 2 trial of the sitravatinib and Opdivo combination therapy for the evaluation of its safety and efficacy in the treatment of non-small cell lung cancer.
- PR Newswire•3 months ago
Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference
SAN DIEGO , Nov. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare ...
- PR Newswire•3 months ago
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The data will be presented today in a poster and also in an oral presentation on Saturday, November 10th. The ongoing Phase 2 clinical trial is evaluating the safety and efficacy of sitravatinib in combination with an anti-PD-1 immune checkpoint inhibitor, in patients who have experienced documented disease progression following prior checkpoint inhibitor therapy. Efficacy data were recently presented at the October 2018 European Society for Medical Oncology (ESMO) Congress.
- PR Newswire•3 months ago
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The data will be presented today in a poster and also in an oral presentation on Sunday, November 11th. The clinical trial is a Phase 2 study evaluating the efficacy and safety of mocetinostat in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in patients with NSCLC who have experienced documented disease progression following prior treatment with an immune checkpoint inhibitor.
